BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...president and CEO Allan Jones also announced plans to step down this year.Musculoskeletal disease company Dyne Therapeutics Inc....
BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

...lymphoma 6 DMPK – Dystrophia myotonica-protein kinaseSARS-CoV-2 S – SARS-CoV-2 spike protein TFRC (TFR) (CD71) – Transferrin receptor Danielle Golovin Dyne Therapeutics Inc. University...
BioCentury | Jan 6, 2021
Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

...the same tissue-targeting goal as the antibody-oligonucleotide conjugates developed by Avidity Biosciences Inc. (NASDAQ:RNA) and Dyne Therapeutics Inc....
...product than typical antibody conjugation methods.TARGETSTNC (TN) – Tenascin C Karen Tkach Tuzman Ionis Pharmaceuticals Inc. Aro Biotherapeutics Co. Dyne Therapeutics Inc. Avidity...
BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...in which two other biopharmas went public, with one gaining and the other ceding value. Dyne Therapeutics Inc....
BioCentury | Sep 18, 2020
Finance

Data Byte: IPO enthusiasm gives Dyne first-day pop as queue continues to grow

...upsized offering; its aftermarket gains of $4.90 to $23.90 lifted its valuation to nearly $1 billion.Dyne Therapeutics Inc....
...joined the IPO queue in September alone, including preclinical exosome therapeutics company Codiak Biosciences Inc. Virginia Li IPO Dyne Therapeutics Inc....
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...industry. Dyne, Silence join NASDAQ queueTwo weeks after raising $115 million in a crossover-heavy series B round, Dyne Therapeutics Inc....
...Myers Squibb Co. Forbius Takeda Pharmaceutical Co. Ltd. Blackstone Group Bio-Thera Solutions Ltd. BeiGene Ltd. Prelude Therapeutics Inc. Silence Therapeutics plc Sirnaomics Inc. RNAimmune Inc. Dyne Therapeutics Inc. ReViral...
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

...succeeds Lesley Stolz, who stepped down as EVP and CBO in November. Muscle diseases company Dyne Therapeutics Inc....
...NASDAQ:VIR), Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) and Sangamo Therapeutics Inc. (NASDAQ:SGMO). Robin Sawka, BioCentury Staff Blackstone Group Ribometrix Inc. Dyne Therapeutics Inc. Annexon...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

...chief development officer. She was SVP and head of regulatory affairs at Novartis’ oncology unit. Dyne Therapeutics Inc....
...was VP of clinical development at Flexion Therapeutics (NASDAQ:FLXN). Hongjiang Li and Elizabeth S. Eaton, Staff Writers Dyne Therapeutics Inc. Imara...
BioCentury | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

...at Pierre Fabre Group and SVP of the Pierre Fabre innovation fund. Muscle disease company Dyne Therapeutics Inc....
...$150M Fund” ). BioCentury Staff Vertex Pharmaceuticals Inc. Nektar Therapeutics Sangamo Therapeutics Inc. Neurocrine Biosciences Inc. Neovacs S.A. Ascletis Pharmaceuticals Co. Ltd. 4BIO Capital Dyne Therapeutics Inc. Avidity...
BioCentury | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

...Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc....
Items per page:
1 - 10 of 14
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...president and CEO Allan Jones also announced plans to step down this year.Musculoskeletal disease company Dyne Therapeutics Inc....
BioCentury | Jan 16, 2021
Translation in Brief

Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more

...lymphoma 6 DMPK – Dystrophia myotonica-protein kinaseSARS-CoV-2 S – SARS-CoV-2 spike protein TFRC (TFR) (CD71) – Transferrin receptor Danielle Golovin Dyne Therapeutics Inc. University...
BioCentury | Jan 6, 2021
Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

...the same tissue-targeting goal as the antibody-oligonucleotide conjugates developed by Avidity Biosciences Inc. (NASDAQ:RNA) and Dyne Therapeutics Inc....
...product than typical antibody conjugation methods.TARGETSTNC (TN) – Tenascin C Karen Tkach Tuzman Ionis Pharmaceuticals Inc. Aro Biotherapeutics Co. Dyne Therapeutics Inc. Avidity...
BioCentury | Sep 19, 2020
Finance

Athira, Compass IPOs help quartet push biopharmas’ 2020 NASDAQ haul above $9B

...in which two other biopharmas went public, with one gaining and the other ceding value. Dyne Therapeutics Inc....
BioCentury | Sep 18, 2020
Finance

Data Byte: IPO enthusiasm gives Dyne first-day pop as queue continues to grow

...upsized offering; its aftermarket gains of $4.90 to $23.90 lifted its valuation to nearly $1 billion.Dyne Therapeutics Inc....
...joined the IPO queue in September alone, including preclinical exosome therapeutics company Codiak Biosciences Inc. Virginia Li IPO Dyne Therapeutics Inc....
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...industry. Dyne, Silence join NASDAQ queueTwo weeks after raising $115 million in a crossover-heavy series B round, Dyne Therapeutics Inc....
...Myers Squibb Co. Forbius Takeda Pharmaceutical Co. Ltd. Blackstone Group Bio-Thera Solutions Ltd. BeiGene Ltd. Prelude Therapeutics Inc. Silence Therapeutics plc Sirnaomics Inc. RNAimmune Inc. Dyne Therapeutics Inc. ReViral...
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

...succeeds Lesley Stolz, who stepped down as EVP and CBO in November. Muscle diseases company Dyne Therapeutics Inc....
...NASDAQ:VIR), Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) and Sangamo Therapeutics Inc. (NASDAQ:SGMO). Robin Sawka, BioCentury Staff Blackstone Group Ribometrix Inc. Dyne Therapeutics Inc. Annexon...
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

...chief development officer. She was SVP and head of regulatory affairs at Novartis’ oncology unit. Dyne Therapeutics Inc....
...was VP of clinical development at Flexion Therapeutics (NASDAQ:FLXN). Hongjiang Li and Elizabeth S. Eaton, Staff Writers Dyne Therapeutics Inc. Imara...
BioCentury | Oct 1, 2019
Company News

Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

...at Pierre Fabre Group and SVP of the Pierre Fabre innovation fund. Muscle disease company Dyne Therapeutics Inc....
...$150M Fund” ). BioCentury Staff Vertex Pharmaceuticals Inc. Nektar Therapeutics Sangamo Therapeutics Inc. Neurocrine Biosciences Inc. Neovacs S.A. Ascletis Pharmaceuticals Co. Ltd. 4BIO Capital Dyne Therapeutics Inc. Avidity...
BioCentury | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

...Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc....
Items per page:
1 - 10 of 14